11:20 AM EDT, 08/13/2024 (MT Newswires) -- Adial Pharmaceuticals ( ADIL ) said Tuesday it is partnering with Boudicca Dx to progress regulatory strategy for its companion diagnostic genetic test for its lead investigational asset, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder.

Boudicca will help ensure it is validated both technically and clinically per the US Food and Administration guidelines, Adial said.

The company said its companion diagnostic is intended to accompany AD04 in identifying potential patients, including recruitment for its planned phase 3 program.